Stock Performance and Price Movement
The stock opened sharply lower today, declining by 4.98% from its previous close, and remained at the intraday low of Rs.131.6 throughout the trading session. This marks the eighteenth consecutive day of losses for Trident Texofab Ltd, during which the stock has shed approximately 51.87% of its value. The current price is substantially below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, underscoring the prevailing bearish momentum.
In comparison, the broader Sensex index opened 265.21 points lower and is trading at 83,930.80, down 0.36% for the day. Notably, the Sensex remains 2.65% shy of its 52-week high of 86,159.02 and has recorded a three-week consecutive rise, gaining 2.93% over that period. This divergence highlights the underperformance of Trident Texofab relative to the broader market.
Long-Term Performance and Market Context
Over the past year, Trident Texofab Ltd has delivered a negative return of 17.23%, contrasting sharply with the Sensex’s positive 10.15% gain and the BSE500’s 12.75% rise. The stock’s 52-week high was Rs.379, indicating a steep decline from its peak. This underperformance is further reflected in the company’s Mojo Score of 26.0 and a Mojo Grade of Strong Sell, which was downgraded from Sell on 3 Feb 2026.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Financial Metrics and Valuation
Trident Texofab Ltd’s long-term fundamental strength remains subdued, with an average Return on Capital Employed (ROCE) of 6.88%. The company’s ability to service debt is limited, as evidenced by a high Debt to EBITDA ratio of 6.83 times, indicating elevated leverage relative to earnings before interest, taxes, depreciation, and amortisation.
Despite these concerns, the company has reported positive quarterly results for the last four consecutive quarters. The highest quarterly PBDIT reached Rs.2.48 crores, with an operating profit to net sales ratio peaking at 8.10%. Additionally, the highest quarterly profit before tax excluding other income was Rs.1.12 crores. These figures suggest some operational resilience amid the challenging market environment.
From a valuation standpoint, the company holds a fair position with a ROCE of 7.4 and an Enterprise Value to Capital Employed ratio of 2.7. The stock currently trades at a discount relative to its peers’ average historical valuations. However, the PEG ratio stands elevated at 7.6, reflecting the disparity between profit growth and stock price performance. Over the past year, profits have increased by 62.6%, contrasting with the negative stock returns.
Shareholding and Market Capitalisation
The majority of Trident Texofab Ltd’s shares are held by non-institutional investors. The company’s market capitalisation grade is rated 4, indicating a mid-tier market cap within its sector. The stock’s day performance today underperformed its sector by 4.37%, further emphasising the relative weakness in investor sentiment towards the company.
Holding Trident Texofab Ltd from Garments & Apparels? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Key Concerns
The stock’s persistent decline over the last eighteen trading sessions, combined with its underperformance relative to the broader market and sector, reflects ongoing challenges in maintaining investor confidence. The high leverage ratio and modest returns on capital employed highlight structural financial constraints. While quarterly profit growth has been positive, it has not translated into stock price appreciation, as indicated by the elevated PEG ratio and the current discount to peer valuations.
Market Environment and Sectoral Context
The Garments & Apparels sector, in which Trident Texofab Ltd operates, has experienced mixed performance in recent months. The company’s stock has notably lagged behind sector averages, with a day’s underperformance of 4.37%. The broader market’s recent gains contrast with the stock’s downward trajectory, underscoring the divergence in performance within the sector.
Technical Indicators
Technically, the stock’s position below all major moving averages signals a sustained bearish trend. The absence of any intraday recovery from the opening gap down today further confirms the prevailing negative sentiment. The 52-week low of Rs.131.6 represents a critical support level that the stock has breached, marking a significant milestone in its price decline.
Conclusion
Trident Texofab Ltd’s fall to a 52-week low of Rs.131.6 on 12 Feb 2026 reflects a combination of financial leverage concerns, underwhelming long-term returns, and a sustained negative price trend. Despite positive quarterly earnings growth, the stock has not been able to regain momentum, continuing to underperform both its sector and the broader market indices. The company’s current valuation metrics and shareholding pattern provide additional context to its market position amid ongoing challenges.
Unlock special upgrade rates for a limited period. Start Saving Now →
